Radius Health Inc. (NASDAQ:RDUS) saw strong trading volume on Wednesday . 2,566,318 shares traded hands during trading, an increase of 302% from the previous session’s volume of 638,546 shares.The stock last traded at $54.40 and had previously closed at $48.98.

A number of analysts have issued reports on the stock. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. HC Wainwright began coverage on shares of Radius Health in a research note on Monday, May 23rd. They set a “buy” rating and a $55.00 target price on the stock. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a research note on Tuesday, May 31st. Finally, Cowen and Company began coverage on shares of Radius Health in a research note on Friday, May 6th. They set an “outperform” rating on the stock. Three investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $70.07.

The stock’s market cap is $2.28 billion. The firm has a 50 day moving average price of $40.54 and a 200-day moving average price of $35.30.

A number of institutional investors recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP bought a new position in Radius Health during the fourth quarter valued at approximately $1,362,000. Nationwide Fund Advisors raised its position in Radius Health by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 24,238 shares of the biopharmaceutical company’s stock valued at $1,492,000 after buying an additional 437 shares during the period. Rhumbline Advisers raised its position in Radius Health by 12.8% in the fourth quarter. Rhumbline Advisers now owns 31,671 shares of the biopharmaceutical company’s stock valued at $1,949,000 after buying an additional 3,585 shares during the period. Swiss National Bank raised its position in Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,222,000 after buying an additional 600 shares during the period. Finally, Mutual of America Capital Management LLC raised its position in Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares during the period.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.